Zoetis, Inc.
The world's largest animal health company — $9.3 billion in revenue, blockbuster pet therapeutics like Apoquel and Simparica Trio, and an unmatched R&D pipeline spanning 300+ product lines across 100+ countries.
Business Overview
What does Zoetis do, and why is it the undisputed leader?
Zoetis is not a generic pharmaceutical company — it is the world's largest pure-play animal health company, and the only one of its scale exclusively focused on the health of animals. Spun off from Pfizer in 2013, Zoetis has leveraged 70+ years of veterinary science heritage to build a dominant franchise across companion animal and livestock markets in over 100 countries.
The company's portfolio spans 300+ product lines covering vaccines, parasiticides, anti-infectives, medicated feed additives, diagnostics, and a revolutionary new class of monoclonal antibody pain therapeutics. Zoetis operates across eight species — dogs, cats, horses, cattle, swine, poultry, fish, and sheep — making it the most diversified animal health platform on Earth.
What sets Zoetis apart is its innovation-driven growth model. The company spends over $600 million annually on R&D — more than any competitor in animal health — and has delivered a stream of first-in-class therapeutics. Librela (for dogs) and Solensia (for cats) are the world's first monoclonal antibody treatments for osteoarthritis pain in animals, opening an entirely new treatment category with no direct competitors.
Zoetis also owns Vetscan diagnostics, providing point-of-care and reference lab testing that creates a data feedback loop: vets who diagnose with Zoetis equipment are more likely to prescribe Zoetis treatments. This integrated diagnostics-to-therapeutics ecosystem deepens customer relationships and creates powerful switching costs.
Companion Animal
67.8% of revenue. Apoquel/Cytopoint (dermatology), Simparica Trio (parasiticides), Librela/Solensia (pain), plus vaccines and diagnostics. Growing 10%+ annually driven by pet humanisation trends.
Livestock
31.3% of revenue. Cattle, swine, poultry, and aquaculture vaccines, anti-infectives, and parasiticides. Stable, recurring revenue driven by global protein demand and food safety regulations.
Diagnostics & Other
~1% of revenue but strategically critical. Vetscan point-of-care diagnostics, reference labs, and data analytics. Creates an integrated diagnostics-to-therapeutics ecosystem that deepens vet relationships.
Financial Fundamentals
Three tests every quality business must pass
Moat Analysis
Five dimensions that determine competitive durability
Brand Loyalty & Pricing Power
9/10Zoetis is the most trusted name in veterinary medicine. Veterinarians prescribe Apoquel, Simparica Trio, and Librela by name — not by generic. Pet owners increasingly treat animals as family members and rarely negotiate on price for their pet's health. Zoetis commands premium pricing with minimal pushback, evidenced by consistent mid-single-digit price increases annually.
High Barriers to Entry
9/10Developing animal therapeutics requires multi-year regulatory approvals across species and geographies — often 7-10 years from lab to market. Zoetis holds hundreds of patents, operates 25+ manufacturing sites globally, and invests $600M+ annually in R&D. Its Librela/Solensia monoclonal antibody platform represents a $2B+ investment that no competitor has replicated. The regulatory and capital barriers are enormous.
High Switching Costs
8/10Veterinarians build their entire practice workflow around Zoetis products — Vetscan diagnostics, treatment protocols, and patient data are deeply integrated. Once a vet prescribes Apoquel for a dog's dermatitis and sees results, switching to an unproven alternative risks patient outcomes and vet reputation. Livestock producers face similar lock-in with vaccination programmes that must remain consistent across herds.
Network Effect
6/10Moderate network effects through the diagnostics-to-therapeutics data flywheel. More vets using Vetscan diagnostics generates more clinical data, which improves Zoetis's R&D targeting, producing better therapeutics that attract more vets. The company also benefits from the largest global sales force in animal health (10,000+ reps), creating a self-reinforcing distribution advantage. However, this is not a true platform network effect.
Economies of Scale
8/10$9.3B in revenue makes Zoetis nearly 3x larger than its nearest pure-play competitor (Elanco at ~$4.4B). This scale enables $600M+ in annual R&D investment that smaller competitors cannot match, a 10,000+ person global sales force covering 100+ countries, and 25+ manufacturing sites with purchasing leverage on raw materials. The result: 37% EBITDA margins that continue to expand as high-margin companion animal products grow faster.
Bull & Bear Thesis
Both sides of the coin — so you can decide for yourself
Bull Case
Bear Case
Growth Drivers
Where the next wave of revenue comes from
Librela & Solensia Ramp
The world's first monoclonal antibody pain treatments for dogs and cats are still in early innings. Librela exceeded $500M in its first full year and is expanding geographically. With osteoarthritis affecting 40% of dogs and 90% of senior cats, peak sales estimates range from $2-3 billion annually for the franchise.
Diagnostics Expansion
The Vetscan diagnostics portfolio creates a virtuous data flywheel — vets who diagnose with Zoetis equipment prescribe Zoetis therapeutics. Point-of-care testing, reference labs, and AI-driven clinical decision support tools are expanding the addressable market and deepening customer relationships.
Emerging Markets & Livestock
Growing middle-class populations in Asia, Latin America, and Africa are driving increased protein consumption and pet ownership. Global meat production is projected to grow 15% by 2031, requiring more veterinary interventions. Zoetis's presence in 100+ countries positions it as the primary beneficiary of rising animal health standards worldwide.
Innovation Pipeline
Zoetis invests $600M+ annually in R&D — more than any competitor. The pipeline includes next-generation dermatology treatments, novel parasiticide combinations, gene therapy for livestock diseases, and expansion of the monoclonal antibody platform into new indications beyond pain. Over 200 projects are in active development.
Investment Risks
Every investment has risks — here is what could go wrong
Librela Adverse Event Risk
FDA has received adverse event reports including neurological symptoms in some dogs after Librela treatment. While these reports affect a small percentage of patients, increased regulatory scrutiny or a label change could significantly slow adoption of Zoetis's most important growth product. Veterinarian confidence is critical to the franchise's success.
High SeverityApoquel Patent Expiry & Generic Erosion
Apoquel (oclacitinib) is a $1B+ blockbuster franchise facing increasing generic competition as key patents expire. Generic erosion in international markets is already underway. While Zoetis is transitioning customers to Cytopoint (injectable, harder to replicate), a rapid generic launch in the US would create a meaningful revenue headwind.
High SeverityLivestock Market Cyclicality
The livestock segment (31% of revenue) is exposed to commodity cycles, disease outbreaks, and trade disruptions. African Swine Fever, avian influenza, and cattle disease outbreaks can cause sudden demand shifts. Trade tensions between the US, China, and EU can disrupt protein markets and reduce producer spending on animal health products.
Medium SeverityValuation Premium Compression
Zoetis trades at a premium multiple to both the healthcare sector and animal health peers, reflecting its growth profile and moat quality. Any slowdown in companion animal growth, Librela setbacks, or broader market de-rating of growth stocks could compress the multiple significantly. The stock has historically traded at 30-40x forward earnings.
Medium SeverityValuation & Intrinsic Value
What is this business actually worth?
As of 18 February 2026, Zoetis, Inc. (ZTS) is trading at approximately 23% below its estimated intrinsic value based on our discounted cash flow model. With 23% ROIC, a dominant market position in the structurally growing animal health industry, blockbuster franchises like Librela and Simparica Trio, and $2.6 billion in annual free cash flow, Zoetis offers a meaningful margin of safety despite the slightly elevated leverage on its balance sheet.
Download the Mintin5 app for the latest update on valuation details, fair value estimates, and margin of safety calculations for ZTS and 100+ other stocks.
Download Mintin5 for Valuation DetailsDisclaimer
This research is for educational purposes only and does not constitute financial advice. The information presented is based on publicly available data and our independent analysis. Always do your own research and consult a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results.